Report : Europe GMP Cell Therapy Consumables Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)
At 27.2% CAGR, the Europe GMP Cell Therapy Consumables Market is speculated to be worth US$ 20,569.16 Million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Europe GMP cell therapy consumables market was valued at US$ 4,827.85 million in 2022 and is expected to reach US$ 20,569.16 million by 2028, registering a CAGR of 27.2% from 2022 to 2028. Growing regulatory approvals for cell and gene therapy product and increase in strategic collaborations are the critical factors attributed to the Europe GMP cell therapy consumables market expansion.
Drug discovery is a long process that comprises various steps such as early discovery, preclinical phase, clinical phase, and regulatory approval. The process tremendously involves the use of cell therapy consumables to achieve the desired results. According to the World Health Organization, ~10 million deaths due to cancer were recorded in 2020, and the most common cancers are breast, lung, colon, rectum, and prostate cancers. Various research studies have shown positive outcomes of drugs that can effectively treat cancer, neurological disorders, autoimmune disorders, and other chronic disorders. Therefore, the rising prevalence of chronic disorders propels the demand for research and development (R&D) activities. In addition, the increase in the incidence of various rare disorders such as amyloidosis, Adrenoleukodystrophy, and Ehlers-Danlos syndrome has increased the R&D activities for drug development.
Moreover, numerous biotechnology companies operating in the market are collaborating with each other to accelerate R&D activities on a global level. For instance, in October 2022, Century Therapeutics and Bristol Myers Squibb announced the research collaboration and license agreement to develop and commercialize up to four induced pluripotent stem cells (“iPSC”) derived, engineered natural killer cell (“iNK”) and/or T cell (“iT”) programs for hematologic malignancies and solid tumors. Additionally, the rising demand for personalized and regenerative medicine has further boosted the growth of the cell therapy consumables market. Therefore, an increase in drug discovery and R&D requires good manufacturing practices and obtaining desired results from these activities, GMP consumables are required. Thus, an increase in research & development activities along with a surge in drug discovery has tremendously increased the use of good manufacturing practice (GMP) cell therapy consumables and driven the growth of the Europe GMP cell therapy consumables market.
The increase in strategic collaborations among market players for the development of cell therapy has propelled the use of GMP cell therapy consumables to achieve the desired products, which drives the growth of the Europe GMP cell therapy consumables market..
On the contrary, stringent regulatory policies hurdles the growth of Europe GMP cell therapy consumables market.
- Based on product, the Europe GMP cell therapy consumables market is segmented into kits, reagents/molecular biology reagents, growth factors/cytokines and interleukins (including protein and nucleic acid purification buffers), and others. The kits segment held 54.8% share of Europe GMP cell therapy consumables market in 2022, amassing US$ 2,647.50 million. It is projected to garner US$ 11,172.01 million by 2028 to expand at 27.1% CAGR during 2022–2028.
- Based on cell therapy, the Europe GMP cell therapy consumables market is segmented into NK cell therapy, stem cell therapy, T-cell therapy, and others. The T-cell therapy segment held 60.2% share of Europe GMP cell therapy consumables market in 2022, amassing US$ 2,908.68 million. It is projected to garner US$ 12,217.17 million by 2028 to expand at 27.0% CAGR during 2022–2028.
- Based on process, the Europe GMP cell therapy consumables market is segmented into cell collection and characterization/sorting and separation, cell culture and expansion/preparation, cryopreservation, cell processing and formulation, cell isolation and activation, cell distribution/handling, process monitoring and control/readministration/quality assurance, and others. The cell collection and characterization/sorting and separation segment held 36.1% share of Europe GMP cell therapy consumables market in 2022, amassing US$ 1,742.01 million. It is projected to garner US$ 7,434.11 million by 2028 to expand at 27.4% CAGR during 2022–2028.
- Based on end use, the Europe GMP cell therapy consumables market is segmented into clinical, commercial, and research. The clinical segment held 71.4% share of Europe GMP cell therapy consumables market in 2022, amassing US$ 3,449.50 million. It is projected to garner US$ 14,941.57 million by 2028 to expand at 27.7% CAGR during 2022–2028.
- Based on country, the Europe GMP cell therapy consumables market is segmented into France, Italy, Germany, Spain, the UK, and the Rest of Europe. Our regional analysis states that Germany captured 29.5% share of of Europe GMP cell therapy consumables market in 2022. It was assessed at US$ 1,421.80 million in 2022 and is likely to hit US$ 5,921.86 million by 2028, exhibiting a CAGR of 26.8% during the forecast period.
Key players dominating the Europe GMP cell therapy consumables market are Bio-Techne Corp, BPS Bioscience Inc, Corning Inc, FUJIFILM Irvine Scientific Inc, Global Life Sciences Solutions USA LLC, Lonza Group AG, Merck KGaA, Miltenyi Biotec BV & Co KG, Sartorius AG, and Thermo Fisher Scientific Inc, among others.
- In June 2021, Sartorius, through its subgroup Sartorius Stedim Biotech acquired a majority stake in the reagent manufacturer CellGenix GmbH. The company produces and markets cell culture components, such as growth factors, cytokines, and media in GMP quality for manufacturing cell and gene therapy products. Sartorius has acquired 51% of the company and at the beginning of 2023 and 2026, it plans to acquire the remaining shares of CellGenix.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com